Welgene BiotechLtd Balance Sheet Health
Financial Health criteria checks 3/6
Welgene BiotechLtd has a total shareholder equity of NT$300.3M and total debt of NT$127.4M, which brings its debt-to-equity ratio to 42.4%. Its total assets and total liabilities are NT$548.2M and NT$247.9M respectively.
Key information
42.4%
Debt to equity ratio
NT$127.45m
Debt
Interest coverage ratio | n/a |
Cash | NT$197.13m |
Equity | NT$300.27m |
Total liabilities | NT$247.89m |
Total assets | NT$548.16m |
Recent financial health updates
No updates
Recent updates
Is Welgene Biotech Co.,Ltd.'s (GTSM:6661) 4.7% Dividend Sustainable?
Mar 19Are Welgene BiotechLtd's (GTSM:6661) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 10Welgene Biotech Co.,Ltd.'s (GTSM:6661) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Jan 13Know This Before Buying Welgene Biotech Co.,Ltd. (GTSM:6661) For Its Dividend
Dec 10Financial Position Analysis
Short Term Liabilities: 6661's short term assets (NT$306.3M) exceed its short term liabilities (NT$127.9M).
Long Term Liabilities: 6661's short term assets (NT$306.3M) exceed its long term liabilities (NT$120.0M).
Debt to Equity History and Analysis
Debt Level: 6661 has more cash than its total debt.
Reducing Debt: 6661's debt to equity ratio has increased from 5.7% to 42.4% over the past 5 years.
Debt Coverage: 6661's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if 6661's interest payments on its debt are well covered by EBIT.